Abstract:Epithelial ovarian cancer (OC) is typically diagnosed at a late stage and, despite treatment with cytoreductive surgery and chemotherapy, 70-80% of patients relapse and eventually die due to the disease. Major challenges to improve patient outcomes are to overcome therapy resistance and to individually tailor therapy. Uncovering the molecular drivers of OC, especially in the most common subgroup high-grade serous (HGS), will help develop novel therapeutic strategies to meet these challenges. Using the Cancer Genome Atlas (TCGA) data, we observed that a locus in 3q26.2, near the EVI1 oncogene, was the most significantly amplified region in HGS OC, occurring in more than 80% of those tumors. We validated these findings in an OC dataset from the Hartwig Medical Foundation and in OC cell lines from the DepMap database. Furthermore, HGS OC had the highest mean copy number of the 3q26.2 locus co-occurring with high mean EVI1 expression among all tumor entities in the pan-cancer TCGA dataset. These EVI1 expression levels are significantly higher than in normal fallopian tube, from which HGS OC most likely arises. EVI1 overexpression promotes leukemogenesis in 3q26-rearranged acute myeloid leukemia (AML), as a result of chromosomal translocations that enable hijacking of hyperactive enhancers. Here, we hypothesize that EVI1 also plays a crucial role in OC development, but that its aberrant expression in this disease is driven by the amplification of yet undiscovered regulatory elements near EVI1. We showed that EVI1-positive OC cell lines, of which the majority are HGS, are EVI1-dependent and harbor a ~200 kb amplified region near EVI1. This region interacts with the EVI1 promoter (4C-Seq), is characterized by open chromatin (ATAC-Seq), and shows high levels of H3K27 acetylation (H3K27ac ChIP-Seq), suggesting the presence of an active enhancer. Furthermore, based upon H3K27ac signal, we identified within this region a super-enhancer of approximately 65 kb. In OC cell lines without detectable EVI1 levels or cell lines from other cancer subtypes, such as breast and colon cancer, this location had no active enhancer and did not loop to the EVI1 promoter. Altogether, these data point to the generation of a hyperactive super-enhancer driving EVI1 overexpression in OC. These findings emphasize the importance of epigenetic control in the regulation of EVI1 expression, as previously shown in 3q26-rearranged AML. Since OC tumor cell lines are strongly dependent on EVI1, interference with this super-enhancer, leading to loss of EVI1 expression, could be exploited to inhibit tumor growth. For this purpose, we generated GFP-tagged EVI1 cell line models (e.g. SKOV3), which will be used to discover small molecules to target the activity of this super-enhancer. In conclusion, we discovered a new mechanism of enhancer-mediated overexpression of the EVI1 oncogene as a molecular driver in ovarian cancer, with possible implications for therapy. Citation Format: Leonie Smeenk, Sabrina Kruse, Roger Mulet-Lazaro, Ingrid Boere, John Martens, Stefan Gröschel, Claudia Scholl, Stefan Fröhling, Ruud Delwel. Tumor-specific super-enhancer drives overexpression of EVI1 in ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3040.

Human EVI2B Acts As a Janus-faced Oncogene/antioncogene by Differently Affecting As Per Cancer Type Neoplastic Cells Growth and Immune Infiltration

Clinical Features and Prognostic Implications of Ecotropic Viral Integration Site 1 (EVI1) in Childhood Acute Lymphoblastic Leukemia

Bioinformatics and in vitro-based comprehensive analysis of EVI2A expression and its immunological and prognostic significance in Kidney Renal Clear Cell Carcinoma

EVI5 is an Oncogene That Regulates the Proliferation and Metastasis of NSCLC Cells

Integrative Bioinformatics and in Vitro Exploration of EVI2A Expression: Unraveling Its Immunological and Prognostic Implications in Kidney Renal Clear Cell Carcinoma

EVI2B is a Prognostic Biomarker and is Correlated with Monocyte and Macrophage Infiltration in Osteosarcoma Based on an Integrative Analysis

EVA1B Facilitates Esophageal Squamous Carcinoma Progression and Recruitment of Immunosuppressive Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

Increased expression of ecotropic viral integration site 2A indicates a poor prognosis and promotes osteosarcoma evolution through activating MEK/ERK pathway

The reciprocal link between EVI1 and miRNAs in human malignancies

EVI1 Expression Predicts Outcome in Higher-Risk Myelodysplastic Syndrome Patients.

EVI1 overexpression promotes ovarian cancer progression by regulating estrogen signaling

Downregulation of EVI1 Expression Inhibits Cell Proliferation and Induces Apoptosis in Hilar Cholangiocarcinoma Via the PTEN/AKT Signalling Pathway

Abstract 3040: Tumor-specific super-enhancer drives overexpression of EVI1 in ovarian cancer

EVI1 dysregulation: impact on biology and therapy of myeloid malignancies

EVI1 Interferes with Myeloid Maturation via Transcriptional Repression of Cebpa, via Binding to Two Far Downstream Regulatory Elements

Clinical Features and Early Effect in EVI1 Positive Acute Myeloid Lleukemia

Promoted cancer growth by stimulating cell proliferation and decreasing apoptosis using a lentivirus-based EphB2 RNAi in pancreatic carcinoma CFPAC-1 cells.

Oral Squamous Cell Carcinoma-Derived EVs Promote Tumor Progression by Regulating Inflammatory Cytokines and the IL-17A-induced Signaling Pathway

[Clinical Features and Early Treatment Effects in Intermediate Risk and Poor Risk Acute Myeloid Leukemia with EVI1 Positive].

[Clinical and Biological Characteristics of Childhood Acute Myeloid Leukemia with EVI1 Gene Positive Expression].

High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy